Pain Management Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Fibromyalgia: Changes Since 1990

Since the release of criteria for the diagnosis of fibromyalgia in 1990, much more is known about this syndrome.

Short-Term Opioid Use for LBP

There is evidence of short-term efficacy of opioids for treatment of chronic low back pain compared with placebo, according to a new study.

NSAIDs, Anticoagulants, Bleeding Risk

Use of an NSAID or aspirin in patients with venous thromboembolism receiving anticoagulant therapy is tied to increased risk of bleeding.

FDA Approves Opioid Overdose Reversal

The FDA has approved Evzio (naloxone HCl injection; Kaléo, Inc.) for the emergency treatment of known or suspected opioid overdose.

Can Pain Relievers Fight "Superbugs"?

Common NSAIDs may help to prevent the rise of antibiotic-resistant bacteria ("superbugs") by providing an alternative treatment for infections.

Brain Scans for Headaches Unnecessary

Research has found that routine headache neuroimaging is frequently ordered by doctors for patients suffering from headaches.

Chart: Narcotic Analgesics

Review this updated chart on narcotic analgesics for quick information when you need it.

New Drug Product: Zubsolv

Maintenance treatment of opioid dependence, as part of a complete treatment plan to include counseling and psychosocial support.

Videos

News

Predicting Sick Leave for Back Pain with New Scale

A new user-friendly 10-item rating scale is useful for predicting the duration of sick leave in patients with acute lumbar back pain.

FDA: Corticosteroid Injections Need Label Warning

The FDA is warning patients and healthcare professionals about the potential for rare but serious adverse events associated with injection of corticosteroids into the epidural space of the spine.

FDA Panel Recommends Against New Pain Drug

QRxPharma announced that the FDA Anesthetic and Analgesic Drug Products Advisory Committee has voted against recommending the revised New Drug Application (NDA) for Moxduo (morphine sulfate and oxycodone hydrochloride).

Marcaine Recalled Due to Visible Particulates

Hospira announced a voluntary nationwide recall of one lot of 0.25% Marcaine (bupivacaine HCl) injection, single-dose 10mL vials due to discolored solution with visible particles embedded in the glass as well as the presence of discolored solution.

Featured courses from mycme

Pain Management Workshop (Pharmacology Credit)External web site

This program will discuss the causes of chronic pain as well as pharmacological options for ...

CE 3.00 Credits

Debridement Training: Principles & PracticeExternal web site

This course offers practicing physicians, mid-level practitioners, nurses and other allied health professionals a comprehensive ...

CME|CE 4.00 Credits

The Safe Use of Opioids in the Treatment of PainExternal web site

To minimize the risk of abuse and addiction, evidence-based prescribing practices must be used when ...

CME|CE 0.50 Credits
More myCME courses »

Sign Up for Free e-newsletters